Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Sarepta Therapeutics Inc. shares soared after the company said it was cutting more than a third of its workforce and that its ...

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...

Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...